Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer

Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were div...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2022, Vol.2022, p.9810036-10
Main Authors: Hou, Jie, Shi, Ke, Liu, Yao, Chen, Jialiang, Ran, Chongping, Wang, Xianbo
Format: Article
Language:English
Subjects:
Ablation
Adjuvant therapy
Adjuvants
Cancer therapies
Chemotherapy
Chinese medicine
FDA approval
Hepatitis
Hospitals
Liver cancer
Medical prognosis
Mortality
Patients
Survival
Survival analysis
Traditional Chinese medicine
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3
cites cdi_FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3
container_end_page 10
container_issue
container_start_page 9810036
container_title Evidence-based complementary and alternative medicine
container_volume 2022
creator Hou, Jie
Shi, Ke
Liu, Yao
Chen, Jialiang
Ran, Chongping
Wang, Xianbo
description Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were divided into TCM and control groups according to whether the patients took TCM for ≥3 months. There were 1,111 patients in the TCM group and 748 in the control group. Univariate and multivariate Cox regression analyses were used to analyze the factors affecting the 3-year survival of patients with PLC. To reduce selection bias, 1 : 1 propensity score matching (PSM) was performed between the two groups. The overall survival outcomes were evaluated using the Kaplan–Meier (K–M) survival curve, and the log-rank test was used to compare the differences in survival curves. Results. After multivariate Cox regression analysis, TCM was an independent favorable factor for the 3-year survival of patients with PLC (adjusted hazard ratio (aHR) 0.359, 95% confidence interval (CI) 0.292–0.441, P
doi_str_mv 10.1155/2022/9810036
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8947932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2643814509</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3</originalsourceid><addsrcrecordid>eNp9kc1rFDEYh4MotlZvniXgRdC1-ZpJchHK0qqwxUK34C1k8-FkmU22ycyU_vdN3XWxHjzlhffJk_fND4C3GH3GuGlOCSLkVAqMEG2fgWPMGZ4xIsTzQ81_HoFXpawRIpJz_hIc0YYyjKk4BvHce2eGApOHy6xtGEKKuofzLkRXHLx0NphawjO7HicdB7jsXNbbe5giHDoHr8c8haneqIIrPQQXq-wuDB28ymGj8z1chMllONfRuPwavPC6L-7N_jwBNxfny_m32eLH1-_zs8XMMCaGmZNSrzjjEiFJCEWmXTEvm4ZRt2o9r20pPWqksdYK7K0UhPrWcKGb1iNn6Qn4svNux9XGWVOnyrpX291IKumgnnZi6NSvNCkh66uUVMGHvSCn29GVQW1CMa7vdXRpLIq0jNGWSEEr-v4fdJ3GXD_xN0UFZg2Slfq0o0xOpWTnD8NgpB6DVI9Bqn2QFX_39wIH-E9yFfi4A2pQVt-F_-seAPnzplI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2643814509</pqid></control><display><type>article</type><title>Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content (ProQuest)</source><creator>Hou, Jie ; Shi, Ke ; Liu, Yao ; Chen, Jialiang ; Ran, Chongping ; Wang, Xianbo</creator><contributor>Tao, Jun Yan ; Jun Yan Tao</contributor><creatorcontrib>Hou, Jie ; Shi, Ke ; Liu, Yao ; Chen, Jialiang ; Ran, Chongping ; Wang, Xianbo ; Tao, Jun Yan ; Jun Yan Tao</creatorcontrib><description>Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were divided into TCM and control groups according to whether the patients took TCM for ≥3 months. There were 1,111 patients in the TCM group and 748 in the control group. Univariate and multivariate Cox regression analyses were used to analyze the factors affecting the 3-year survival of patients with PLC. To reduce selection bias, 1 : 1 propensity score matching (PSM) was performed between the two groups. The overall survival outcomes were evaluated using the Kaplan–Meier (K–M) survival curve, and the log-rank test was used to compare the differences in survival curves. Results. After multivariate Cox regression analysis, TCM was an independent favorable factor for the 3-year survival of patients with PLC (adjusted hazard ratio (aHR) 0.359, 95% confidence interval (CI) 0.292–0.441, P&lt;0.001). Before and after PSM, the 3-year overall survival rates were 33.3% and 54% in the control group and 79.7% and 69.7% in the TCM group, respectively. The 3-year mortality risk in the TCM group was lower than that in the control group for different PLC subgroups. Conclusions. TCM adjuvant therapy increased the 3-year overall survival rate of patients with PLC.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2022/9810036</identifier><identifier>PMID: 35341138</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Ablation ; Adjuvant therapy ; Adjuvants ; Cancer therapies ; Chemotherapy ; Chinese medicine ; FDA approval ; Hepatitis ; Hospitals ; Liver cancer ; Medical prognosis ; Mortality ; Patients ; Survival ; Survival analysis ; Traditional Chinese medicine ; Tumors</subject><ispartof>Evidence-based complementary and alternative medicine, 2022, Vol.2022, p.9810036-10</ispartof><rights>Copyright © 2022 Jie Hou et al.</rights><rights>Copyright © 2022 Jie Hou et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Jie Hou et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3</citedby><cites>FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3</cites><orcidid>0000-0002-3593-5741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2643814509/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2643814509?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35341138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tao, Jun Yan</contributor><contributor>Jun Yan Tao</contributor><creatorcontrib>Hou, Jie</creatorcontrib><creatorcontrib>Shi, Ke</creatorcontrib><creatorcontrib>Liu, Yao</creatorcontrib><creatorcontrib>Chen, Jialiang</creatorcontrib><creatorcontrib>Ran, Chongping</creatorcontrib><creatorcontrib>Wang, Xianbo</creatorcontrib><title>Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer</title><title>Evidence-based complementary and alternative medicine</title><addtitle>Evid Based Complement Alternat Med</addtitle><description>Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were divided into TCM and control groups according to whether the patients took TCM for ≥3 months. There were 1,111 patients in the TCM group and 748 in the control group. Univariate and multivariate Cox regression analyses were used to analyze the factors affecting the 3-year survival of patients with PLC. To reduce selection bias, 1 : 1 propensity score matching (PSM) was performed between the two groups. The overall survival outcomes were evaluated using the Kaplan–Meier (K–M) survival curve, and the log-rank test was used to compare the differences in survival curves. Results. After multivariate Cox regression analysis, TCM was an independent favorable factor for the 3-year survival of patients with PLC (adjusted hazard ratio (aHR) 0.359, 95% confidence interval (CI) 0.292–0.441, P&lt;0.001). Before and after PSM, the 3-year overall survival rates were 33.3% and 54% in the control group and 79.7% and 69.7% in the TCM group, respectively. The 3-year mortality risk in the TCM group was lower than that in the control group for different PLC subgroups. Conclusions. TCM adjuvant therapy increased the 3-year overall survival rate of patients with PLC.</description><subject>Ablation</subject><subject>Adjuvant therapy</subject><subject>Adjuvants</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Chinese medicine</subject><subject>FDA approval</subject><subject>Hepatitis</subject><subject>Hospitals</subject><subject>Liver cancer</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Traditional Chinese medicine</subject><subject>Tumors</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kc1rFDEYh4MotlZvniXgRdC1-ZpJchHK0qqwxUK34C1k8-FkmU22ycyU_vdN3XWxHjzlhffJk_fND4C3GH3GuGlOCSLkVAqMEG2fgWPMGZ4xIsTzQ81_HoFXpawRIpJz_hIc0YYyjKk4BvHce2eGApOHy6xtGEKKuofzLkRXHLx0NphawjO7HicdB7jsXNbbe5giHDoHr8c8haneqIIrPQQXq-wuDB28ymGj8z1chMllONfRuPwavPC6L-7N_jwBNxfny_m32eLH1-_zs8XMMCaGmZNSrzjjEiFJCEWmXTEvm4ZRt2o9r20pPWqksdYK7K0UhPrWcKGb1iNn6Qn4svNux9XGWVOnyrpX291IKumgnnZi6NSvNCkh66uUVMGHvSCn29GVQW1CMa7vdXRpLIq0jNGWSEEr-v4fdJ3GXD_xN0UFZg2Slfq0o0xOpWTnD8NgpB6DVI9Bqn2QFX_39wIH-E9yFfi4A2pQVt-F_-seAPnzplI</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Hou, Jie</creator><creator>Shi, Ke</creator><creator>Liu, Yao</creator><creator>Chen, Jialiang</creator><creator>Ran, Chongping</creator><creator>Wang, Xianbo</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3593-5741</orcidid></search><sort><creationdate>2022</creationdate><title>Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer</title><author>Hou, Jie ; Shi, Ke ; Liu, Yao ; Chen, Jialiang ; Ran, Chongping ; Wang, Xianbo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Ablation</topic><topic>Adjuvant therapy</topic><topic>Adjuvants</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Chinese medicine</topic><topic>FDA approval</topic><topic>Hepatitis</topic><topic>Hospitals</topic><topic>Liver cancer</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Traditional Chinese medicine</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hou, Jie</creatorcontrib><creatorcontrib>Shi, Ke</creatorcontrib><creatorcontrib>Liu, Yao</creatorcontrib><creatorcontrib>Chen, Jialiang</creatorcontrib><creatorcontrib>Ran, Chongping</creatorcontrib><creatorcontrib>Wang, Xianbo</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Psychology Journals</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hou, Jie</au><au>Shi, Ke</au><au>Liu, Yao</au><au>Chen, Jialiang</au><au>Ran, Chongping</au><au>Wang, Xianbo</au><au>Tao, Jun Yan</au><au>Jun Yan Tao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><addtitle>Evid Based Complement Alternat Med</addtitle><date>2022</date><risdate>2022</risdate><volume>2022</volume><spage>9810036</spage><epage>10</epage><pages>9810036-10</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were divided into TCM and control groups according to whether the patients took TCM for ≥3 months. There were 1,111 patients in the TCM group and 748 in the control group. Univariate and multivariate Cox regression analyses were used to analyze the factors affecting the 3-year survival of patients with PLC. To reduce selection bias, 1 : 1 propensity score matching (PSM) was performed between the two groups. The overall survival outcomes were evaluated using the Kaplan–Meier (K–M) survival curve, and the log-rank test was used to compare the differences in survival curves. Results. After multivariate Cox regression analysis, TCM was an independent favorable factor for the 3-year survival of patients with PLC (adjusted hazard ratio (aHR) 0.359, 95% confidence interval (CI) 0.292–0.441, P&lt;0.001). Before and after PSM, the 3-year overall survival rates were 33.3% and 54% in the control group and 79.7% and 69.7% in the TCM group, respectively. The 3-year mortality risk in the TCM group was lower than that in the control group for different PLC subgroups. Conclusions. TCM adjuvant therapy increased the 3-year overall survival rate of patients with PLC.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>35341138</pmid><doi>10.1155/2022/9810036</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-3593-5741</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1741-427X
ispartof Evidence-based complementary and alternative medicine, 2022, Vol.2022, p.9810036-10
issn 1741-427X
1741-4288
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8947932
source Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content (ProQuest)
subjects Ablation
Adjuvant therapy
Adjuvants
Cancer therapies
Chemotherapy
Chinese medicine
FDA approval
Hepatitis
Hospitals
Liver cancer
Medical prognosis
Mortality
Patients
Survival
Survival analysis
Traditional Chinese medicine
Tumors
title Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A39%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Traditional%20Chinese%20Medicine%20Adjuvant%20Therapy%20on%20the%20Survival%20of%20Patients%20with%20Primary%20Liver%20Cancer&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Hou,%20Jie&rft.date=2022&rft.volume=2022&rft.spage=9810036&rft.epage=10&rft.pages=9810036-10&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2022/9810036&rft_dat=%3Cproquest_pubme%3E2643814509%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-e99ab74790092230c6b4f95543eb6f7e9999f059cddd81fd9823f6c78a56f0ed3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2643814509&rft_id=info:pmid/35341138&rfr_iscdi=true